$
127.240
+1.94(1.548%)1D
  • Overview
  • Forecast
  • Valuation
  • Earnings
Line
Line
|
Candle
Candle
1D
5D
1M
3M
6M
YTD
1Y
5Y
High
128.320
Open
126.785
VWAP
--
Vol
81.30K
Mkt Cap
7.04B
Low
126.785
Amount
--
EV/EBITDA(TTM)
67.90
Total Shares
55.88M
EV
6.86B
EV/OCF(TTM)
44.99
P/S(TTM)
10.36
Repligen Corporation is a global life sciences company that develops and commercializes bioprocessing technologies and systems. Its focus areas are Filtration and Fluid Management, Chromatography, Process Analytics and Proteins. Its filtration products are used in process development and process scale (clinical and commercial) production. Its XCell ATF systems are used in upstream perfusion (continuous) and N-1 (intensified fed-batch or hybrid perfusion) cell culture processing. Its chromatography franchise includes several products used in downstream purification, development, manufacturing and quality control of biological drugs. Its process analytics products complement and support its filtration, chromatography and protein franchises. Its TangenX product portfolio includes flat sheet (FS) tangential flow filtration (TFF) cassettes used primarily in downstream and ultrafiltration processes. Its desktop portfolio includes MAVERICK and MAVEN, REBEL, and ZipChip.
Show More

Market Estimates

Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2026Q1
FY2025Q4
FY2025Q3
193.45M
+14.35%
0.478
+22.65%
191.31M
+14.18%
0.492
+11.85%
175.16M
+13.1%
0.400
-6.98%
Estimates Revision
The market is revising Upward the revenue expectations for Repligen Corporation (RGEN) for FY2025, with the revenue forecasts being adjusted by 0.8% over the past three months. During the same period, the stock price has changed by -7.79%.
Revenue Estimates for FY2025
Revise Upward
up Image
+0.8%
In Past 3 Month
EPS Estimates for FY2025
Revise Upward
up Image
+0.33%
In Past 3 Month
Stock Price
Go Down
down Image
-7.79%
In Past 3 Month
14 Analyst Rating
up Image
39.11% Upside
Wall Street analysts forecast RGEN stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for RGEN is 177.00 USD with a low forecast of 130.00 USD and a high forecast of 207.00  USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
10 Buy
4 Hold
0 Sell
Moderate Buy
up Image
39.11% Upside
Current: 127.240
sliders
Low
130.00
Averages
177.00
High
207.00
Stephens
Steven Etoch
initiated
$160
2025-07-21
Reason
Stephens analyst Steven Etoch resumed coverage of Repligen with an Overweight rating and $160 price target. The firm views Repligen as the leader within the bioprocessing industry. It faces industry tailwinds from the increase in the late stage pipeline of biologics and biosimilars entering the market continue which continue to drive an increasing need for bioprocessing capabilities, the analyst tells investors in a research note.
Barclays
Overweight
initiated
$150
2025-06-24
Reason
Barclays initiated coverage of Repligen with an Overweight rating and $150 price target. The firm says that as a bioprocessing pure-play, it likes Repligen's positioning in the current macro tape. Bioprocessing continues to be Barclays' most preferred subsector given its relative insulation from the major macro headwinds impacting tools, and Repligen is a particularly attractive asset given its heavier weighting towards the clinic, the analyst tells investors in a research note.
Canaccord Genuity
Kyle Mikson
Hold
Maintains
$170 → $150
2025-04-16
Reason
Canaccord analyst Kyle Mikson lowered the firm's price target on Repligen to $150 from $170 and keeps a Hold rating on the shares.
Evercore ISI Group
Daniel Markowitz
Hold
Initiates
$155
2025-03-18
Reason
Evercore ISI initiated coverage of Repligen with an In Line rating and $155 price target. The firm sees the company as a high quality pure play bioprocess supplier with $649M of revenue and a market cap of about $8B, the analyst tells investors in a research note. After two consecutive years of organic declines, Repligen looks positioned to benefit from market recovery and continue to grow more than 500-1000 bps above market growth rate amid outperformance driven by differentiated products and higher clinical mix, the firm added.
JP Morgan
Rachel Vatnsdal
Buy
Maintains
$190 → $200
2025-02-21
Reason
RBC Capital
Conor McNamara
Buy
Maintains
$203 → $205
2025-02-21
Reason

Valuation Metrics

The current forward P/E ratio for Repligen Corp (RGEN.O) is 67.76, compared to its 5-year average forward P/E of 87.77. For a more detailed relative valuation and DCF analysis to assess Repligen Corp 's fair value, click here.

Forward PE

StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
Fair
5Y Average PE
87.77
Current PE
67.76
Overvalued PE
109.32
Undervalued PE
66.22

Forward EV/EBITDA

StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
Fair
5Y Average EV/EBITDA
58.79
Current EV/EBITDA
46.97
Overvalued EV/EBITDA
73.78
Undervalued EV/EBITDA
43.79

Forward PS

StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
Undervalued
5Y Average PS
14.89
Current PS
9.15
Overvalued PS
18.56
Undervalued PS
11.23

Financials

Annual
Quarterly
FY2025Q2
YoY :
+18.36%
182.37M
Total Revenue
FY2025Q2
YoY :
+238.45%
11.71M
Operating Profit
FY2025Q2
YoY :
+347.64%
14.87M
Net Income after Tax
FY2025Q2
YoY :
+333.33%
0.26
EPS - Diluted
FY2025Q1
YoY :
-70.90%
10.58M
Free Cash Flow
FY2025Q2
YoY :
-0.34%
49.98
Gross Profit Margin - %
FY2025Q2
YoY :
-100.00%
N/A
FCF Margin - %
FY2025Q2
YoY :
+277.31%
8.15
Net Margin - %
FY2025Q2
YoY :
-100.00%
N/A
ROIC

Trading Trends

Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
3.3M
USD
1
3-6
Months
4.1M
USD
1
6-9
Months
3.4M
USD
1
0-12
Months
3.2M
USD
1
Bought
0-3
0
0.0
USD
Months
3-6
1
37.7K
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
Hedge Fund
Hedge Funds areBuying! The buying amount has increased 135.49% over the last quarter.
Sold
0-3
Months
0.0
Volume
0
3-6
Months
242.2K
Volume
6
6-9
Months
586.1K
Volume
10
0-12
Months
0.0
Volume
0
Bought
0-3
0
0.0
Volume
Months
3-6
1
129.8K
Volume
Months
6-9
5
55.1K
Volume
Months
0-12
0
0.0
Volume
Months
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
0.0
USD
0
6-9
Months
0.0
USD
0
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months

RGEN News & Events

Events Timeline

2025-07-29 (ET)
2025-07-29
07:38:30
Repligen sees FY25 non-GAAP EPS $1.65-$1.72, consensus $1.68
select
2025-07-29
07:36:25
Repligen reports Q2 adjusted EPS 37c, consensus 39c
select
2025-04-29 (ET)
2025-04-29
07:36:57
Repligen sees FY25 adjusted EPS $1.63-$1.72, consensus $1.71
select
Sign Up For More Events

News

9.5
07-29NASDAQ.COM
PinnedRepligen Corp Q2 Profit Climbs
9.5
07-29Newsfilter
PinnedRepligen Reports Second Quarter 2025 Financial Results and Updates Full Year 2025 Financial Guidance
2.0
07-18Yahoo Finance
Repligen, Bruker, Fortrea, Azenta, and Biogen Stocks Trade Down, What You Need To Know
Sign Up For More News

FAQ

arrow icon

What is Repligen Corp (RGEN) stock price today?

The current price of RGEN is 127.24 USD — it has increased 1.55 % in the last trading day.

arrow icon

What is Repligen Corp (RGEN)'s business?

arrow icon

What is the price predicton of RGEN Stock?

arrow icon

What is Repligen Corp (RGEN)'s revenue for the last quarter?

arrow icon

What is Repligen Corp (RGEN)'s earnings per share (EPS) for the last quarter?

arrow icon

What changes have occurred in the market's expectations for Repligen Corp (RGEN)'s fundamentals?

arrow icon

How many employees does Repligen Corp (RGEN). have?

arrow icon

What is Repligen Corp (RGEN) market cap?